Silencing of KIAA1429, a N6‐methyladenine methyltransferase, inhibits the progression of colon adenocarcinoma via blocking the hypoxia‐inducible factor 1 signalling pathway

Abstract KIAA1429 is an important ‘writer’ of the N6‐methyladenine (m 6 A) modification, which is involved in tumour progression. This study was conducted to explore the mechanism of action of KIAA1429 in colon adenocarcinoma (COAD). KIAA1429 ‐silenced COAD cell and xenograft tumour models were constructed, and the function of KIAA1429 was explored through a series of in vivo and in vitro assays. The downstream mechanisms of KIAA1429 were explored using transcriptome sequencing. Dimethyloxalylglycine (DMOG), an activator of HIF‐1α , was used for feedback verification. The expression of KIAA1429 in COAD tumour tissues and cells was elevated, and KIAA1429 exhibited differential expression at different stages of the tumour. Silencing of KIAA1429 inhibited the proliferation, migration, and invasion of HT29 and HCT116 cells. The expression levels of NLRP3 , GSDMD and Caspase‐1 were decreased in KIAA1429 ‐silenced HT29 cells, indicating the pyroptotic activity was inhibited. Additionally, KIAA1429 silencing inhibited the growth of tumour xenograft. Transcriptome sequencing and reverse transcription quantitative polymerase chain reaction revealed that after KIAA1429 silencing, the expression of AKR1C1 , AKR1C2 , AKR1C3 and RDH8 was elevated, and the expression of VIRMA , GINS1 , VBP1 and ARF3 was decreased. In HT29 cells, KIAA1429 silencing blocked the HIF‐1 signalling pathway, accompanied by the decrease in AKT1 and HIF‐1α protein levels. The activation of HIF‐1 signalling pathway, mediated by DMOG, reversed the antitumour role of KIAA1429 silencing. KIAA1429 silencing inhibits COAD development by blocking the HIF‐1 signalling pathway.